Posts for Protagonist Therapeutics, Inc ($PTGX)

Explore Protagonist Therapeutics' Q4 2024 financial report showcasing $434.4M revenue, $275.2M net income, and a strong 'Buy' recommendation for investors seeking growth in biotech.

Explore Protagonist Therapeutics, Inc.'s 8-K filing from February 21, 2025, detailing significant events for investors. Get insights on stock information, financial status, and more.

Explore Protagonist Therapeutics, Inc.'s 8-K filing from January 1, 2025, detailing stock info, compliance, and operational status. Stay updated on PTGX's market position.